Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience
American Journal of Transplantation · 2023
DOI: 10.1016/j.ajt.2023.04.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Transplantation, 2023. Verfasst von Emma L Heise und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Antibodies, Lung Transplantation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Zentrum für Infektionsforschung.
Abstract (Originalsprache)
Pretransplant allosensitization to human leukocyte antigens (HLA) increases the recipient's waiting list time and mortality in lung transplantation. Rather than waiting for crossmatch-negative donors, since 2013, recipients with preformed donor-specific antiHLA antibodies (pfDSA) have been managed with repeated IgA- and IgM-enriched intravenous immunoglobulin (IgGAM) infusions, usually in combination with plasmapheresis before IgGAM and a single dose of antiCD20 antibody. This retrospective study presents our 9-year experience with patients transplanted with pfDSA. Records of patients transplanted between February 2013 and May 2022 were reviewed. Outcomes were compared between patients with pfDSA and those without any de novo donor-specific antiHLA antibodies. The median follow-up time was 50 months. Of the 1,043 patients who had undergone lung transplantation, 758 (72.7%) did not develop any early donor-specific antiHLA antibodies, and 62 (5.9%) patients exhibited pfDSA. Among the 52 (84%) patients who completed treatment, pfDSA was cleared in 38 (73%). In pfDSA vs control patients and at 8-year follow-up, respectively, graft survival (%) was 75 vs 65 (P = .493) and freedom from chronic lung allograft dysfunction (%) was 63 vs 65 (P = .525). In lung transplantation, crossing the preformed HLA-antibody barrier is safe using a treatment protocol based on IgGAM. Patients with pfDSA have a good 8-year graft survival rate and freedom from chronic lung allograft dysfunction, similar to control patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
- Department of Transplantation Immunology, Hannover Medical School, Hannover, Germany.
- Department of Respiratory Medicine,Hannover Medical School,Hannover,Germany; Member of the German Center for Lung Research (DZL), Hannover/Heidelberg, Germany.
- Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany; Medical Faculty, Saint-Petersburg State University, Saint-Petersburg, Russia.
- Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
- Department of Pediatric Pneumology Allergology and Neonatology, Hannover Medical School, Hannover, Germany; Member of the German Center for Lung Research (DZL), Hannover/Heidelberg, Germany.
Förderung
- Deutsches Zentrum für Infektionsforschung
Zitieren
APA
Heise, E. L., Chichelnitskiy, E., Greer, M., Franz, M., Aburahma, K., Iablonskii, P., de Manna, N. D., Christoph, S., Verboom, M., Hallensleben, M., Boethig, D., Avsar, M., Welte, T., Schwerk, N., Sommer, W., Haverich, A., Warnecke, G., Kuehn, C., Falk, C., …, & Ius, F. (2023). Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2023.04.034
Vancouver
Heise EL, Chichelnitskiy E, Greer M, Franz M, Aburahma K, Iablonskii P, et al. Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience. American Journal of Transplantation. 2023. doi:10.1016/j.ajt.2023.04.034
BibTeX
@article{Heise2023,
author = {Heise, Emma L and Chichelnitskiy, Evgeny and Greer, Mark and Franz, Maximilian and Aburahma, Khalil and Iablonskii, Pavel and de Manna, Nunzio D and Christoph, Stella and Verboom, Murielle and Hallensleben, Michael and Boethig, Dietmar and Avsar, Murat and Welte, Tobias and Schwerk, Nicolaus and Sommer, Wiebke and Haverich, Axel and Warnecke, Gregor and Kuehn, Christian and Falk, Christine and Salman, Jawad and Ius, Fabio},
title = {Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience},
journal = {American Journal of Transplantation},
year = {2023},
doi = {10.1016/j.ajt.2023.04.034}
}
EUVIMED